Want to see SYK full AI Analyst Report?
SYK Stock Chart & Stats
$330.25
$11.28(3.54%)
At close: 4:00 PM EDT
$330.25
$11.28(3.54%)
Day’s Range― - ―
52-Week Range$281.00 - $401.99
Previous CloseN/A
Volume2.37M
Average Volume (3M)2.41M
Market Cap
$135.04B
Enterprise Value$139.27K
Total Cash (Recent Filing)$2.96B
Total Debt (Recent Filing)$15.23B
Price to Earnings (P/E)39.7
Beta0.55
Next Earnings
Oct 29, 2026EPS Estimate
3.57Next Dividend Ex-DateN/A
Dividend Yield1%
Share Statistics
EPS (TTM)8.73
Shares Outstanding383,360,750
10 Day Avg. Volume2,380,506
30 Day Avg. Volume2,414,967
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$380.57Price Target Upside15.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
EPS Forecast (FY)14.97
Revenue Forecast (FY)$27.26B
Bulls Say, Bears Say
Bulls Say
Scale & Margin ProfileStryker’s revenue scale has grown materially while maintaining industry-leading gross margins (~60–64%) and healthy operating margins. That combination supports durable investment in R&D, commercial expansion and margin resilience across surgical and capital businesses over the next several quarters.
Free Cash Flow GenerationOperating cash flow and free cash flow have meaningfully increased (OCF ~$5.4B and FCF ~$4.6B TTM), with FCF tracking earnings at ~0.78–0.85. Strong cash conversion underpins M&A funding, capital spending for robotics installs, and resumed buybacks while preserving liquidity for multi‑year strategic priorities.
Robotics & Product Innovation MomentumMako is delivering record installations and Stryker launched Mako RPS in the U.S., expanding robotics into total knee procedures. Combined with the Ortho Tech reorg, this creates structural advantage: integrated robotics, instruments and services that can drive recurring capital and consumable revenue over many quarters.
Bears Say
Sizeable Absolute DebtAlthough leverage has improved, Stryker carries large absolute debt (~$14–15B). That level raises refinancing and interest‑rate sensitivity and constrains flexibility for large, immediate bolt‑on transactions or margin cushions if cash generation weakens, a persistent multi‑month governance consideration.
Ongoing Cyber Remediation CostsResidual impacts from a prior cyber incident — production shutdowns, remediation costs, idle/absorption and higher IT spend — continue to pressure margins and operating cadence. These remediation effects can persist for multiple quarters and influence capital allocation and near‑term EPS trajectory.
Supply & Launch Timing DisruptionOperational disruptions (Inari supply backorders and slower-than-expected product ramps) produced lost sales and uneven launch timing. For a procedure‑driven business, recurring supply or ramp delays create durable volatility in revenue and could delay capture of long‑term upsides from new products.
SYK FAQ
What was Stryker Corp’s price range in the past 12 months?
Stryker Corp lowest stock price was $281.00 and its highest was $401.99 in the past 12 months.
What is Stryker Corp’s market cap?
Stryker Corp’s market cap is $135.04B.
When is Stryker Corp’s upcoming earnings report date?
Stryker Corp’s upcoming earnings report date is Oct 29, 2026 which is in 90 days.
How were Stryker Corp’s earnings last quarter?
Stryker Corp released its earnings results on Jul 30, 2026. The company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.488 by $0.202.
Is Stryker Corp overvalued?
According to Wall Street analysts Stryker Corp’s price is currently Undervalued.
Does Stryker Corp pay dividends?
Stryker Corp pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 1%. See more information on Stryker Corp dividends here
What is Stryker Corp’s EPS estimate?
Stryker Corp’s EPS estimate is 3.57.
How many shares outstanding does Stryker Corp have?
Stryker Corp has 383,360,750 shares outstanding.
What happened to Stryker Corp’s price movement after its last earnings report?
Stryker Corp reported an EPS of $3.69 in its last earnings report, beating expectations of $3.488. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Stryker Corp?
Currently, no hedge funds are holding shares in SYK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stryker Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$380.57 (15.24% Upside)
$380.57 (15.24% Upside)
Blogger Sentiment
Bullish
SYK Sentiment 90%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $99.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.70%
12-Months-Change
Fundamentals
Return on Equity
1.00%
Trailing 12-Months
Asset Growth
0.62%
Trailing 12-Months
Company Description
Stryker Corp
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
SYK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad recovery and operational momentum: solid organic growth (9%), a strong adjusted EPS beat (+17.9%), expanding margins, record Mako performance, multiple product launches and healthy cash generation/backlog. Key negatives were an acute supply disruption in peripheral vascular (Inari) that drove a U.S. vascular decline (‑6.7%), lingering costs and absorption effects from the prior cybersecurity incident, and some launch timing variability. Management expects backorders to be manageable by end of Q3 and reiterated confidence in the full‑year outlook and capital demand, so positives materially outweigh manageable near‑term headwinds.View all SYK earnings summariesSYK Net sales Breakdown
62.30% MedSurg and Neurotechnology
37.70% Orthopaedics and Spine

SYK Stock 12 Month Forecast
Average Price Target
$380.57
▲(15.24% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Zimmer Biomet Holdings
―
Ownership Overview
4.00% Insiders
19.34% Mutual Funds
9.13% Other Institutional Investors
46.82% Public Companies and Individual Investors










